Genetics and pain

Keith A Candiotti, Claudia R. Fernandez Robles

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Human beings differ widely in their rating and experience of painful stimulation. There are large variations in interindividual sensitivities to noxious pain, susceptibility to acute or chronic pain (even among patients with the same medical condition), and individual responses to analgesics. These individual responses arise from a multitude of factors, including environmental elements and genetic variations or polymorphisms. Understanding the factors that contribute to patient-related variability in pain behavior and responses to analgesics is critical for the effective treatment of patients and management of their pain. This chapter will review some important pain polymorphisms and how they can influence the pain behavior of patients.Genetic factors (Table 8.1) Mu opioid receptor (MOR) The mu receptor OPRM1 is the primary target site for opioid medications. The gene for this receptor is located on chromosome 6 and is a significant factor in the variability of how a patient responds to opioids. The most common single nucleotide polymorphism (SNP), or basepair change, of the MOR gene consists of a change of adenine to guanine in the 118 position that leads to a substitution of the amino acid asparagine for aspartate. This substitution affects the function of the receptor by increasing its binding affinity for β-endorphins and subsequently affects the action of opioids at the receptor site.

Original languageEnglish (US)
Title of host publicationThe Essence of Analgesia and Analgesics
PublisherCambridge University Press
Pages37-40
Number of pages4
ISBN (Electronic)9780511841378
ISBN (Print)9780521144506
DOIs
StatePublished - Jan 1 2010

Fingerprint

mu Opioid Receptor
Pain
Opioid Analgesics
Analgesics
Endorphins
Chromosomes, Human, Pair 6
Asparagine
Guanine
Acute Pain
Opioid Receptors
Genetic Polymorphisms
Adenine
Amino Acid Substitution
Pain Management
Aspartic Acid
Chronic Pain
Genes
Single Nucleotide Polymorphism
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Candiotti, K. A., & Fernandez Robles, C. R. (2010). Genetics and pain. In The Essence of Analgesia and Analgesics (pp. 37-40). Cambridge University Press. https://doi.org/10.1017/CBO9780511841378.008

Genetics and pain. / Candiotti, Keith A; Fernandez Robles, Claudia R.

The Essence of Analgesia and Analgesics. Cambridge University Press, 2010. p. 37-40.

Research output: Chapter in Book/Report/Conference proceedingChapter

Candiotti, KA & Fernandez Robles, CR 2010, Genetics and pain. in The Essence of Analgesia and Analgesics. Cambridge University Press, pp. 37-40. https://doi.org/10.1017/CBO9780511841378.008
Candiotti KA, Fernandez Robles CR. Genetics and pain. In The Essence of Analgesia and Analgesics. Cambridge University Press. 2010. p. 37-40 https://doi.org/10.1017/CBO9780511841378.008
Candiotti, Keith A ; Fernandez Robles, Claudia R. / Genetics and pain. The Essence of Analgesia and Analgesics. Cambridge University Press, 2010. pp. 37-40
@inbook{ed1740a0c9c849faa438b16dd0fb9824,
title = "Genetics and pain",
abstract = "Introduction Human beings differ widely in their rating and experience of painful stimulation. There are large variations in interindividual sensitivities to noxious pain, susceptibility to acute or chronic pain (even among patients with the same medical condition), and individual responses to analgesics. These individual responses arise from a multitude of factors, including environmental elements and genetic variations or polymorphisms. Understanding the factors that contribute to patient-related variability in pain behavior and responses to analgesics is critical for the effective treatment of patients and management of their pain. This chapter will review some important pain polymorphisms and how they can influence the pain behavior of patients.Genetic factors (Table 8.1) Mu opioid receptor (MOR) The mu receptor OPRM1 is the primary target site for opioid medications. The gene for this receptor is located on chromosome 6 and is a significant factor in the variability of how a patient responds to opioids. The most common single nucleotide polymorphism (SNP), or basepair change, of the MOR gene consists of a change of adenine to guanine in the 118 position that leads to a substitution of the amino acid asparagine for aspartate. This substitution affects the function of the receptor by increasing its binding affinity for β-endorphins and subsequently affects the action of opioids at the receptor site.",
author = "Candiotti, {Keith A} and {Fernandez Robles}, {Claudia R.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1017/CBO9780511841378.008",
language = "English (US)",
isbn = "9780521144506",
pages = "37--40",
booktitle = "The Essence of Analgesia and Analgesics",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Genetics and pain

AU - Candiotti, Keith A

AU - Fernandez Robles, Claudia R.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Introduction Human beings differ widely in their rating and experience of painful stimulation. There are large variations in interindividual sensitivities to noxious pain, susceptibility to acute or chronic pain (even among patients with the same medical condition), and individual responses to analgesics. These individual responses arise from a multitude of factors, including environmental elements and genetic variations or polymorphisms. Understanding the factors that contribute to patient-related variability in pain behavior and responses to analgesics is critical for the effective treatment of patients and management of their pain. This chapter will review some important pain polymorphisms and how they can influence the pain behavior of patients.Genetic factors (Table 8.1) Mu opioid receptor (MOR) The mu receptor OPRM1 is the primary target site for opioid medications. The gene for this receptor is located on chromosome 6 and is a significant factor in the variability of how a patient responds to opioids. The most common single nucleotide polymorphism (SNP), or basepair change, of the MOR gene consists of a change of adenine to guanine in the 118 position that leads to a substitution of the amino acid asparagine for aspartate. This substitution affects the function of the receptor by increasing its binding affinity for β-endorphins and subsequently affects the action of opioids at the receptor site.

AB - Introduction Human beings differ widely in their rating and experience of painful stimulation. There are large variations in interindividual sensitivities to noxious pain, susceptibility to acute or chronic pain (even among patients with the same medical condition), and individual responses to analgesics. These individual responses arise from a multitude of factors, including environmental elements and genetic variations or polymorphisms. Understanding the factors that contribute to patient-related variability in pain behavior and responses to analgesics is critical for the effective treatment of patients and management of their pain. This chapter will review some important pain polymorphisms and how they can influence the pain behavior of patients.Genetic factors (Table 8.1) Mu opioid receptor (MOR) The mu receptor OPRM1 is the primary target site for opioid medications. The gene for this receptor is located on chromosome 6 and is a significant factor in the variability of how a patient responds to opioids. The most common single nucleotide polymorphism (SNP), or basepair change, of the MOR gene consists of a change of adenine to guanine in the 118 position that leads to a substitution of the amino acid asparagine for aspartate. This substitution affects the function of the receptor by increasing its binding affinity for β-endorphins and subsequently affects the action of opioids at the receptor site.

UR - http://www.scopus.com/inward/record.url?scp=85012186696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012186696&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511841378.008

DO - 10.1017/CBO9780511841378.008

M3 - Chapter

SN - 9780521144506

SP - 37

EP - 40

BT - The Essence of Analgesia and Analgesics

PB - Cambridge University Press

ER -